Addressing liver fibrosis with Liposomes targeted to hepatic stellate cells

Liver fibrosis is a chronic disease that results from hepatitis B and C infections, alcohol abuse or metabolic and genetic disorders. Ultimately, progression of fibrosis leads to cirrhosis, a stage of the disease characterized by failure of the normal liver functions. Currently, the treatment of liver fibrosis is mainly based oil the removal of the underlying cause of the disease and liver transplantation, which is the only treatment for patients with advanced fibrosis. Hepatic stellate cells (HSC) are considered to be key players ill the development of liver fibrosis. Chronically activated HSC produces large amounts of extracellular matrix and enhance fibrosis by, secreting a broad spectrum of cytokines that exert pro-fibrotic actions in other cells, and in oil autocrine manner perpetuate their own activation. Therefore, therapeutic interventions that inhibit activation of HSC and its pro-fibrotic activities are currently under investigation worldwide. In the present study we applied targeted liposomes as drug carriers to HSC in the fibrotic liver and explored the potential of these liposomes in antifibrotic therapies. Moreover, we investigated effects of bioactive compounds delivered by these liposomes oil the progression of liver fibrosis. To our knowledge, this is the first study demonstrating that lipid-based drug carriers call be selectively delivered to HSC in the fibrotic liver. By incorporating the bioactive lipid DLPC, these liposomes can modulate different processes such as inflammation and fibrogenesis in the fibrotic liver. This dual functionalily of liposomes as a drug carrier system with intrinsic biological effects may be exploited in new approaches to treat liver fibrosis.